Teva Is Eager to Expand in Specialty Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva’s integration of Barr is ahead of schedule, enabling the generics firm to think about strengthening its branded franchises.
You may also be interested in...
With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations
While the value of Cephalon's pipeline is "modest," the specialty pharma will provide Teva with an expanded portfolio of marketed branded drugs, commercial infrastructure and cost synergies, making integration execution critical.
With Cephalon Deal, Teva Sees Opportunities For Niche Branded Drugs and Drug/Device Combinations
While the value of Cephalon's pipeline is "modest," the specialty pharma will provide Teva with an expanded portfolio of marketed branded drugs, commercial infrastructure and cost synergies, making integration execution critical.
Oral MS Therapies Move Closer, But Still Far From Approval And Adoption
The arrival of an oral therapy for multiple sclerosis moved closer on Sept. 30, but it will still be an uphill climb: first to get past regulators, and then to gain acceptance from a skeptical field of prescribers
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: